Crossmark

Combination immunotherapy with synthetic long peptides and chemotherapy or PD-1 blocker for cancers caused by human papilloma virus type 16

Published Online: 2023-02-13

Published Print: 2023-03

Authors

Melief, Cornelis J.M. https://orcid.org/0000-0001-5709-3584
van der Gracht, Esmé

Wiekmeijer, Anna-Sophia
License Information

Text and Data Mining valid from 2023-02-13

Version of Record valid from 2023-02-13
More Information

Article History

Received: 24 January 2023

Accepted: 24 January 2023

First Online: 13 February 2023

Declarations

:

: All authors are salaried employees of ISA Pharmaceuticals, a biotech company aiming at the development of therapeutic synthetic long peptide vaccines against tumor-associated target molecules, including E6 and E7 of HPV16.

Document is current